The White House
November 6, 2025
ADVANCING MOST-FAVORED-NATION (MFN) PRICING
Today, President Donald J. Trump announced the latest in a series of historic actions to lower prescription drug prices, unveiling landmark agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for some of the world’s most widely used medications.
- The agreement represents an unprecedented reduction in prices for two of the drugs with the highest annual expenditures in the United States—both essential for adults managing diabetes, heart disease (Ozempic and Wegovy only), obesity, and related conditions.
- The prices of Ozempic and Wegovy will drop from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.
- The prices of Zepbound and Orforglipron (pending FDA approval) will fall from $1,086 per month to an average of $346 through TrumpRx.
- If the FDA later approves the Wegovy pill or similar “GLP-1” oral drugs, the initial dose will be priced at $150 per month through TrumpRx.
- These reductions will enable Medicare and Medicaid to cover obesity drugs for adults at dramatically lower costs to taxpayers than under the Biden Administration’s proposals.
- Medicare prices for Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, less than half of the prices previously proposed.
- State Medicaid programs will also have access to these same low prices.
- Medicare beneficiaries will pay a co-pay of just $50 per month.
- Additional reductions have been secured on other Eli Lilly and Novo Nordisk products purchased through TrumpRx:
- Emgality (Eli Lilly) – $299 per pen, a discount of $443 off the list price.
- Trulicity (Eli Lilly) – $389 per month, a discount of $598 off the list price.
- Insulin products (Novo Nordisk) – including NovoLog and Tresiba, will cost $35 per month per supply.
- Both companies have also agreed to:
- Guarantee Most-Favored-Nation prices on all new medicines brought to market.
- Repatriate increased foreign revenue from existing products.
- Provide every State Medicaid program access to MFN drug prices on their products.
INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS
To strengthen the domestic pharmaceutical supply chain, both Eli Lilly and Novo Nordisk are announcing major new investments in U.S. manufacturing:
- Novo Nordisk will invest an additional $10 billion to expand U.S. production capacity, including full-scale domestic production of the Wegovy tablet (pending approval).
- Eli Lilly, under President Trump’s leadership, has announced at least $27 billion in new U.S. manufacturing investments.
MAKING AMERICA HEALTHY AGAIN
President Trump remains committed to ensuring that America’s healthcare system promotes true health and addresses the root causes of chronic disease. Today’s announcements represent historic progress toward that goal.
- According to the Centers for Disease Control and Prevention (CDC), 40% of American adults are obese.
- Obesity is a major driver of chronic disease—raising the risk of type 2 diabetes, hypertension, heart disease, stroke, and certain cancers.
- By making life-changing medications available at affordable prices, today’s agreement represents a historic opportunity to reverse the nation’s obesity epidemic—especially when paired with improved nutrition, physical activity, and lifestyle habits.
The Administration continues to advance its Make America Healthy Again initiative, which focuses on:
- Realigning healthcare incentives.
- Encouraging private-sector collaboration.
- Increasing public awareness about diet and exercise.
- Supporting critical research to prevent and manage chronic disease.
ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION
President Trump is taking decisive action to end a global system that has long allowed other wealthy nations to benefit from America’s pharmaceutical innovation while Americans pay far higher prices.
- Americans pay more than three times what citizens of other OECD nations pay for brand-name drugs, even after accounting for domestic discounts.
- Although the United States represents less than 5% of the world’s population, it contributes roughly 75% of global pharmaceutical profits.
- U.S. taxpayers fund research and development through generous subsidies and healthcare spending, yet manufacturers discount their products abroad—forcing Americans to subsidize both foreign health systems and corporate profits.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST
President Trump continues to deliver on promises that the political establishment claimed were impossible.
- On May 12, 2025, President Trump signed an Executive Order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing the Administration to align U.S. drug prices with those of other advanced nations.
- On July 31, 2025, he sent letters to leading pharmaceutical manufacturers outlining steps required to lower U.S. prescription drug prices to match the lowest global rates.
- Since September 30, 2025, the Administration has announced five major deals with pharmaceutical companies, reducing costs for millions of Americans.
President Trump has been unwavering in his commitment to eliminate unfair and excessive drug pricing:
“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory—effectively subsidizing socialism abroad with skyrocketing prices at home. We spend tremendous amounts of money to provide inexpensive drugs to another country, while Americans pay four or five times more for the same product.”
814 words, 4 minutes read time.
About The Author
